Tirzepatide is a novel medication developed by Eli Lilly and Company for the treatment of type 2 dia****es. It is a once-weekly injectable glucagon-like peptide-1 (GLP-1) receptor agonist that has shown promising results in clinical trials. The recommended starting dose of Tirzepatide 5mg, with gradual titration to a maximum dose of 15 mg based on individual patient response and tolerability.
Visit us:- https://semglu01.bcz.com/2023/....03/13/dosage-and-adm